Dow Inc. is evaluating an exit from its 35 percent stake in Sadara Chemical Co. the $20 billion joint venture with Saudi Aramco, according to multiple reports. The strategic review reflects both cyclical industry pressures and structural headwinds specific to the partnership.
Financial deterioration provides the clearest signal. As of June 30, Dow reported a negative investment balance of $793 million in Sadara—a quantifiable measure of cumulative losses exceeding the original capital commitment. The company suspended recognition of additional losses in Q1 2026, a red flag that further write-downs were likely.
Two narratives explain the divestment consideration. Saudi Aramco could acquire Dow's stake outright, or the companies could solicit bids from strategic or financial investors. No final decision has been made.
The immediate trigger is Middle East conflict. In July, Dow disclosed that regional instability disrupted supply chains, elevated transportation and operating costs, and directly constrained its Middle Eastern joint ventures. The Sadara complex in Jubail, Saudi Arabia—which produces more than 3 million metric tons annually of chemicals and plastics—experienced temporary production shutdowns due to these supply chain breaks.
But the conflict is an accelerant, not the root cause. The global petrochemical sector faces persistent structural oversupply. European producers face rising feedstock costs and tightening emissions regulations. Demand remains stagnant across major end markets. These conditions compress margins industry-wide and make negative-yielding assets untenable for large capital holders.
Dow's portfolio rationalization reflects this reality. The company conducted a major review of European assets in 2024, announced a 13 percent workforce reduction in January, and is now explicitly reassessing non-core holdings. Sadara, despite its scale, has become a portfolio drain rather than a growth engine.
Saudi Aramco, Sadara's co-owner, is pursuing parallel divestitures. The state-owned energy firm is reportedly considering a sale of Arlanxeo, its specialty chemicals unit, as part of a broader capital optimization strategy.
The timing is significant: neither partner benefits from holding a deteriorating asset in a sector facing structural headwinds and geopolitical friction. An exit—whether full or partial—represents capital reallocation toward higher-yielding opportunities.
